CLASS II Device recall · Reported 11 Apr 2018 · FDA Enforcement Report

ImmunoCAP Allergen c6, Amoxicilloyl ( Article number 14-4451-016) recalled

Phadia US is recalling ImmunoCAP Allergen c6, Amoxicilloyl ( Article number 14-4451-016), distributed nationwide in the US. The recall was initiated on 18 Dec 2017 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLots 991DA, exp.2018.04.30 991DC, exp. 2018.07.31 991D7 991D9, exp.2018.02.28
Quantity recalled950 total

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1313-2018
FDA event ID
79444
Recalling firm
Phadia US, Portage, MI
Classification
Class II
Status
Terminated
Recall initiated
18 Dec 2017
FDA classified
5 Apr 2018
Reported
11 Apr 2018
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Labeling Errors

Timeline

18 Dec 2017Recall initiated by company
5 Apr 2018Classified by FDA+108 days
11 Apr 2018Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

The stability specifications of ImmunoCAP Allergen c6, Amoxicilloyl were not met.

Product as listed by the FDA

ImmunoCAP Allergen c6, Amoxicilloyl ( Article number 14-4451-016). ImmunoCAP Specific IgE is an in vitro quantitative assay for the measurement of allergen specific IgE in human serum or plasma; to be used with the instrument Phadia 250, Phadia 1000, Phadia 2500 and Phadia 5000.

Where it was distributed

Nationwide Distribution

Nationwide

Questions about this recall

Why was it recalled?

The stability specifications of ImmunoCAP Allergen c6, Amoxicilloyl were not met.

Which lots are affected?

Lots 991DA, exp.2018.04.30 991DC, exp. 2018.07.31 991D7 991D9, exp.2018.02.28

Where was it sold?

Nationwide Distribution

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 79444

This product is part of a recall event; the main page for the event is ImmunoCAP Allergen c5, Ampicilloyl (article number 14-4450-01) recalled.

ReportedClassRecallCompanyReasonWhere
CLASS IIImmunoCAP Allergen c5, Ampicilloyl (article number 14-4450-01) recalledPhadia USLabeling ErrorsNationwide

More recalls from Phadia US

All 9

Other Test Kits & Diagnostics recalls

All 2,656